{"success":true,"data":{"pressRelease":{"id":"8993","rtpr_id":"nGNXfD2fQ","ticker":"ALLR","exchange":"NASDAQ","all_tickers":["ALLR"],"title":"Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office","author":"Globe Newswire","published_at":"2026-04-27T12:00:02.023Z","article_body":"* Patent expected to be formally granted within three months, subject to\nstandard administrative procedures\n\n\n* Patent would provide exclusivity at least into 2039 for stenoparib when used\nin concert with the stenoparib DRP test\nTARPON SPRINGS, Fla., April 27, 2026 – Allarity Therapeutics, Inc.\n(“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage\npharmaceutical company dedicated to developing stenoparib (2X-121)—a\ndifferentiated, dual PARP and WNT pathway inhibitor— today announced that\nthe United States Patent and Trademark Office (USPTO) has issued a Notice of\nAllowance for its patent application covering the Company’s DRP(®)\ncompanion diagnostic specific to stenoparib.\n\nImportantly, this Notice of Allowance covers multiple claims and represents a\nmajor step in Allarity’s global strategy to expand and protect the\ncommercial potential of stenoparib when selecting patients using its\nproprietary stenoparib DRP(®) test. The patent is expected to be formally\ngranted within three months, subject to standard administrative procedures and\nwould provide exclusivity at least into 2039 for stenoparib when used in\nconcert with the DRP(®) as a companion diagnostic.\n\nThomas Jensen, CEO of Allarity Therapeutics, commented: “This Notice of\nAllowance from the USPTO represents another successful milestone in our\nefforts to secure intellectual property protection for our DRP® technology in\nthe US, the world’s most important pharmaceutical market. Critically, this\npatent maximizes the marketing exclusivity in the US for stenoparib in\npatients selected using the stenoparib DRP test, which is especially important\nas we seek to accelerate stenoparib toward approval for Ovarian and other\ncancers.”\n\nThe allowed claims include methods for predicting clinical benefit based on\ngene expression profiles derived from tumor samples and for selecting those\npatients most likely to benefit from stenoparib treatment.\n\nAllarity previously secured a European and Australian patent for the\nStenoparib DRP(®) and holds 18 granted patents for other drug-specific DRPs,\nincluding eight in the United States. Patent applications for the Stenoparib\nDRP(®) remain pending in Canada, Japan, China, and India.\n\nAbout Stenoparib/2X-121\nStenoparib is an orally available, small-molecule dual-targeted inhibitor of\nPARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant\nattention as emerging therapeutic targets for cancer, principally due to their\nrole in regulating the WNT signaling pathway. Aberrant WNT/β-catenin\nsignaling has been implicated in the development and progression of numerous\ncancers. By inhibiting PARP and blocking WNT pathway activation,\nstenoparib’s unique therapeutic action shows potential as a promising\ntherapeutic for many cancer types, including ovarian cancer, Small Cell Lung\nCancer and colorectal cancer. Allarity has secured exclusive global rights for\nthe development and commercialization of stenoparib, which was originally\ndeveloped by Eisai Co. Ltd. and was formerly known under the names E7449 and\n2X-121. Allarity has two ongoing Phase 2 trial protocols for stenoparib in\nOvarian Cancer patients. In the first, patients who had had 2+ lines of\ntherapy were enrolled on stenoparib and given drug twice daily. This protocol\nhas been closed to further enrollment but continues for the enrolled patients\nwho are still receiving benefit from stenoparib administration. The updated\ndata from this study were presented at the AACR special conference on advances\nin Ovarian Cancer in September 2025. Note that, as these data are from an\nongoing trial, analyses may change as the study fully matures. An amended\nprotocol designed expressly to capitalize on the emerging clinical experience\nwith stenoparib in platinum resistant patients began enrolling patients in the\nsummer of 2025. This amended protocol enrolls only platinum resistant or\nplatinum-ineligible patients and is designed to accelerate the clinical\ndevelopment of stenoparib toward FDA approval. In parallel, a separate Phase 2\ntrial evaluating stenoparib in combination with temozolomide for relapsed\nsmall cell lung cancer (SCLC) began enrolling patients in early 2026 and is\ncurrently enrolling patients across multiple U.S. Veterans Administration (VA)\nsites.\n\nAbout the Drug Response Predictor – DRP(®) Companion Diagnostic\nAllarity uses its drug-specific DRP(®) to select those patients who, by the\ngene expression signature of their cancer, may have a high likelihood of\nbenefiting from a specific drug. By screening patients before treatment, and\nonly treating those patients with a sufficiently high, drug-specific DRP\nscore, the therapeutic benefit rate may be enhanced. The DRP method builds on\nthe comparison of sensitive vs. resistant human cancer cell lines, including\ntranscriptomic information from cell lines, combined with clinical tumor\nbiology filters and prior clinical trial outcomes. DRP is based on messenger\nRNA expression profiles from patient biopsies. The DRP(®) platform has shown\nan ability to provide a statistically significant prediction of the clinical\noutcome from drug treatment in cancer patients across dozens of clinical\nstudies (both retrospective and prospective). The DRP platform, which may be\nuseful in all cancer types and is patented for dozens of anti-cancer drugs,\nhas been extensively published in the peer-reviewed literature.\n\nAbout Allarity Therapeutics\nAllarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage\nbiopharmaceutical company dedicated to developing personalized cancer\ntreatments. The Company is focused on development of stenoparib, a novel\nPARP/tankyrase inhibitor for advanced ovarian cancer patients, using its\nDRP(®) technology to develop a companion diagnostic that can be used to\nselect those patients expected to derive the greatest clinical benefit from\nstenoparib. Allarity is headquartered in the U.S., with a research facility in\nDenmark, and is committed to addressing significant unmet medical needs in\ncancer treatment. For more information, visit www.allarity.com.\n\nFollow Allarity on Social Media\nLinkedIn: https://www.linkedin.com/company/allaritytx/\n\nForward-Looking Statements \nThis press release contains “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act of 1995.\nForward-looking statements provide the Company’s current expectations or\nforecasts of future events. The words “anticipates,” “believe,”\n“continue,” “could,” “estimate,” “expect,” “intends,”\n“may,” “might,” “plan,” “possible,” “potential,”\n“predicts,” “project,” “should,” “would” and similar\nexpressions may identify forward-looking statements, but the absence of these\nwords does not mean that a statement is not forward-looking. These\nforward-looking statements include, but are not limited to, statements\nregarding the expected grant and scope of the U.S. patent for the stenoparib\nDRP® companion diagnostic; the anticipated contribution of this patent to the\nCompany’s global intellectual property strategy; and the Company’s ability\nto advance and commercialize stenoparib and its companion diagnostic. Any\nforward-looking statements in this press release are based on management’s\ncurrent expectations of future events and are subject to multiple risks and\nuncertainties that could cause actual results to differ materially and\nadversely from those set forth in or implied by such forward-looking\nstatements. These risks and uncertainties include, but are not limited to,\nrisks related to the patent grant process, including potential delays or\nchallenges; the Company’s ability to obtain, maintain, and enforce\nintellectual property protection; and broader risks related to the Company’s\nclinical development, regulatory progress, and financial resources. For a\ndiscussion of other risks and uncertainties, and other important factors, any\nof which could cause our actual results to differ from those contained in the\nforward-looking statements, see the section entitled “Risk Factors” in our\nForm 10-K annual report filed with the Securities and Exchange Commission (the\n“SEC”) on March 30, 2026, available at the SEC’s website at www.sec.gov,\nas well as discussions of potential risks, uncertainties and other important\nfactors in the Company’s subsequent filings with the SEC. All information in\nthis press release is as of the date of the release, and the Company\nundertakes no duty to update this information unless required by law.\n\n###\n\nCompany Contact:         \n        investorrelations@allarity.com\n\n        \nMedia Contact:\n        Thomas Pedersen\n        Carrotize PR & Communications\n        +45 6062 9390\n        tsp@carrotize.com\n\nAttachment\n*     Allarity Therapeutics Press Release - Stenoparib DRP Test Has Received a\nNotice of Allowance from the USPTO\n(https://ml-eu.globenewswire.com/Resource/Download/2cf77e8a-17c5-4f0b-ad7f-926b11acc3fa)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/fd1e4c64-f0cf-40e0-a0c9-0be0d6dce544)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXfD2fQ","title":"Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office","author":"Globe Newswire","ticker":"ALLR","created":"2026-04-27T12:00:02.023Z","tickers":["ALLR"],"exchange":"NASDAQ","article_body":"* Patent expected to be formally granted within three months, subject to\nstandard administrative procedures\n\n\n* Patent would provide exclusivity at least into 2039 for stenoparib when used\nin concert with the stenoparib DRP test\nTARPON SPRINGS, Fla., April 27, 2026 – Allarity Therapeutics, Inc.\n(“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage\npharmaceutical company dedicated to developing stenoparib (2X-121)—a\ndifferentiated, dual PARP and WNT pathway inhibitor— today announced that\nthe United States Patent and Trademark Office (USPTO) has issued a Notice of\nAllowance for its patent application covering the Company’s DRP(®)\ncompanion diagnostic specific to stenoparib.\n\nImportantly, this Notice of Allowance covers multiple claims and represents a\nmajor step in Allarity’s global strategy to expand and protect the\ncommercial potential of stenoparib when selecting patients using its\nproprietary stenoparib DRP(®) test. The patent is expected to be formally\ngranted within three months, subject to standard administrative procedures and\nwould provide exclusivity at least into 2039 for stenoparib when used in\nconcert with the DRP(®) as a companion diagnostic.\n\nThomas Jensen, CEO of Allarity Therapeutics, commented: “This Notice of\nAllowance from the USPTO represents another successful milestone in our\nefforts to secure intellectual property protection for our DRP® technology in\nthe US, the world’s most important pharmaceutical market. Critically, this\npatent maximizes the marketing exclusivity in the US for stenoparib in\npatients selected using the stenoparib DRP test, which is especially important\nas we seek to accelerate stenoparib toward approval for Ovarian and other\ncancers.”\n\nThe allowed claims include methods for predicting clinical benefit based on\ngene expression profiles derived from tumor samples and for selecting those\npatients most likely to benefit from stenoparib treatment.\n\nAllarity previously secured a European and Australian patent for the\nStenoparib DRP(®) and holds 18 granted patents for other drug-specific DRPs,\nincluding eight in the United States. Patent applications for the Stenoparib\nDRP(®) remain pending in Canada, Japan, China, and India.\n\nAbout Stenoparib/2X-121\nStenoparib is an orally available, small-molecule dual-targeted inhibitor of\nPARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant\nattention as emerging therapeutic targets for cancer, principally due to their\nrole in regulating the WNT signaling pathway. Aberrant WNT/β-catenin\nsignaling has been implicated in the development and progression of numerous\ncancers. By inhibiting PARP and blocking WNT pathway activation,\nstenoparib’s unique therapeutic action shows potential as a promising\ntherapeutic for many cancer types, including ovarian cancer, Small Cell Lung\nCancer and colorectal cancer. Allarity has secured exclusive global rights for\nthe development and commercialization of stenoparib, which was originally\ndeveloped by Eisai Co. Ltd. and was formerly known under the names E7449 and\n2X-121. Allarity has two ongoing Phase 2 trial protocols for stenoparib in\nOvarian Cancer patients. In the first, patients who had had 2+ lines of\ntherapy were enrolled on stenoparib and given drug twice daily. This protocol\nhas been closed to further enrollment but continues for the enrolled patients\nwho are still receiving benefit from stenoparib administration. The updated\ndata from this study were presented at the AACR special conference on advances\nin Ovarian Cancer in September 2025. Note that, as these data are from an\nongoing trial, analyses may change as the study fully matures. An amended\nprotocol designed expressly to capitalize on the emerging clinical experience\nwith stenoparib in platinum resistant patients began enrolling patients in the\nsummer of 2025. This amended protocol enrolls only platinum resistant or\nplatinum-ineligible patients and is designed to accelerate the clinical\ndevelopment of stenoparib toward FDA approval. In parallel, a separate Phase 2\ntrial evaluating stenoparib in combination with temozolomide for relapsed\nsmall cell lung cancer (SCLC) began enrolling patients in early 2026 and is\ncurrently enrolling patients across multiple U.S. Veterans Administration (VA)\nsites.\n\nAbout the Drug Response Predictor – DRP(®) Companion Diagnostic\nAllarity uses its drug-specific DRP(®) to select those patients who, by the\ngene expression signature of their cancer, may have a high likelihood of\nbenefiting from a specific drug. By screening patients before treatment, and\nonly treating those patients with a sufficiently high, drug-specific DRP\nscore, the therapeutic benefit rate may be enhanced. The DRP method builds on\nthe comparison of sensitive vs. resistant human cancer cell lines, including\ntranscriptomic information from cell lines, combined with clinical tumor\nbiology filters and prior clinical trial outcomes. DRP is based on messenger\nRNA expression profiles from patient biopsies. The DRP(®) platform has shown\nan ability to provide a statistically significant prediction of the clinical\noutcome from drug treatment in cancer patients across dozens of clinical\nstudies (both retrospective and prospective). The DRP platform, which may be\nuseful in all cancer types and is patented for dozens of anti-cancer drugs,\nhas been extensively published in the peer-reviewed literature.\n\nAbout Allarity Therapeutics\nAllarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage\nbiopharmaceutical company dedicated to developing personalized cancer\ntreatments. The Company is focused on development of stenoparib, a novel\nPARP/tankyrase inhibitor for advanced ovarian cancer patients, using its\nDRP(®) technology to develop a companion diagnostic that can be used to\nselect those patients expected to derive the greatest clinical benefit from\nstenoparib. Allarity is headquartered in the U.S., with a research facility in\nDenmark, and is committed to addressing significant unmet medical needs in\ncancer treatment. For more information, visit www.allarity.com.\n\nFollow Allarity on Social Media\nLinkedIn: https://www.linkedin.com/company/allaritytx/\n\nForward-Looking Statements \nThis press release contains “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act of 1995.\nForward-looking statements provide the Company’s current expectations or\nforecasts of future events. The words “anticipates,” “believe,”\n“continue,” “could,” “estimate,” “expect,” “intends,”\n“may,” “might,” “plan,” “possible,” “potential,”\n“predicts,” “project,” “should,” “would” and similar\nexpressions may identify forward-looking statements, but the absence of these\nwords does not mean that a statement is not forward-looking. These\nforward-looking statements include, but are not limited to, statements\nregarding the expected grant and scope of the U.S. patent for the stenoparib\nDRP® companion diagnostic; the anticipated contribution of this patent to the\nCompany’s global intellectual property strategy; and the Company’s ability\nto advance and commercialize stenoparib and its companion diagnostic. Any\nforward-looking statements in this press release are based on management’s\ncurrent expectations of future events and are subject to multiple risks and\nuncertainties that could cause actual results to differ materially and\nadversely from those set forth in or implied by such forward-looking\nstatements. These risks and uncertainties include, but are not limited to,\nrisks related to the patent grant process, including potential delays or\nchallenges; the Company’s ability to obtain, maintain, and enforce\nintellectual property protection; and broader risks related to the Company’s\nclinical development, regulatory progress, and financial resources. For a\ndiscussion of other risks and uncertainties, and other important factors, any\nof which could cause our actual results to differ from those contained in the\nforward-looking statements, see the section entitled “Risk Factors” in our\nForm 10-K annual report filed with the Securities and Exchange Commission (the\n“SEC”) on March 30, 2026, available at the SEC’s website at www.sec.gov,\nas well as discussions of potential risks, uncertainties and other important\nfactors in the Company’s subsequent filings with the SEC. All information in\nthis press release is as of the date of the release, and the Company\nundertakes no duty to update this information unless required by law.\n\n###\n\nCompany Contact:         \n        investorrelations@allarity.com\n\n        \nMedia Contact:\n        Thomas Pedersen\n        Carrotize PR & Communications\n        +45 6062 9390\n        tsp@carrotize.com\n\nAttachment\n*     Allarity Therapeutics Press Release - Stenoparib DRP Test Has Received a\nNotice of Allowance from the USPTO\n(https://ml-eu.globenewswire.com/Resource/Download/2cf77e8a-17c5-4f0b-ad7f-926b11acc3fa)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/fd1e4c64-f0cf-40e0-a0c9-0be0d6dce544)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-27T12:00:02.334031398Z","server_sent_at_ms":1777291202334},"received_at":"2026-04-27T12:00:02.388Z","source_url":"https://www.globenewswire.com/news-release/2026/04/27/3281537/0/en/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office.html"},"analysis":{"id":"6756","press_release_id":"8993","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"regulatory","narrative":"Allarity Therapeutics announced that the USPTO has issued a Notice of Allowance for the patent application covering its stenoparib DRP companion diagnostic.\n\nThe patent is expected to be formally granted within three months and would provide exclusivity for stenoparib at least into 2039 when used with the diagnostic test.\n\nThe company continues to advance stenoparib through two ongoing Phase 2 protocols in Ovarian Cancer and a Phase 2 trial for relapsed small cell lung cancer.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Patent notice secures stenoparib exclusivity through 2039, bolstering the commercial runway for the Phase 2 asset."},"keyFigures":{"drugName":"Stenoparib (2X-121)","phaseOfTrial":"Phase 2"},"quotedText":"This Notice of Allowance from the USPTO represents another successful milestone in our efforts to secure intellectual property protection for our DRP® technology in the US, the world’s most important pharmaceutical market.","namedEntities":{"people":[{"name":"Thomas Jensen","role":"CEO"}],"products":["Stenoparib","2X-121","E7449","DRP"],"companies":[{"name":"Allarity Therapeutics, Inc.","ticker":"ALLR"},{"name":"Eisai Co. Ltd.","relationship":"original developer"},{"name":"U.S. Veterans Administration","relationship":"trial site operator"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Receipt of a Notice of Allowance for a key companion diagnostic patent extends potential exclusivity for stenoparib into 2039, a meaningful commercial milestone for a Phase 2 asset, though not a binary clinical or regulatory approval event."},"tickerRelevance":{"others":[],"primary":"ALLR"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro_cap","eventGravity":"patent_allowance","sectorWeight":"biotech","householdBrandBoost":false}},"event_type":"regulatory","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Allarity Therapeutics announced that the USPTO has issued a Notice of Allowance for the patent application covering its stenoparib DRP companion diagnostic.\n\nThe patent is expected to be formally granted within three months and would provide exclusivity for stenoparib at least into 2039 when used with the diagnostic test.\n\nThe company continues to advance stenoparib through two ongoing Phase 2 protocols in Ovarian Cancer and a Phase 2 trial for relapsed small cell lung cancer.","key_figures":{"drugName":"Stenoparib (2X-121)","phaseOfTrial":"Phase 2"},"named_entities":{"people":[{"name":"Thomas Jensen","role":"CEO"}],"products":["Stenoparib","2X-121","E7449","DRP"],"companies":[{"name":"Allarity Therapeutics, Inc.","ticker":"ALLR"},{"name":"Eisai Co. Ltd.","relationship":"original developer"},{"name":"U.S. Veterans Administration","relationship":"trial site operator"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:1fc968c3ac7f7ebb","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-04-27T15:01:51.847Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"micro_cap","eventGravity":"patent_allowance","sectorWeight":"biotech","householdBrandBoost":false}},"durationMs":138065,"modelName":"glm-4.7"}}